Note: This call for proposals closed on 8 January 2025.

This call consists of prioritized health technology topics under the HTA general track and are proceeding to the following assessments:

• Clinical assessment: Identify and synthesize all eligible clinical studies that report on the benefits and harms relevant to the PICOT clinical research question
• Economic assessment: Economic evaluation (EE), Budget Impact Analysis (BIA) and Household Financial Impact (HFI) Analysis
• ELSHI assessment: Scoping review of ELSHI evidence (and systematic review and primary data collection, if deemed necessary)

The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 4 Call [FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments; and, Cycle 2 topics for Clinical Assessments]

The following are the health technology topics to be funded under this Call for Capsule Proposals:

Clinical Assessment

1. Dexmedetomidine (as hydrochloride) for intensive care unit (ICU) sedation and procedural sedation
2. Glucose (544mL) + amino acids (315mL) + electrocytes + lipids (141mL), 1000mL for disease-related malnutrition in hospitalized patients
3. High protein (as Semi Modular Enteral Nutrition) for protein supplementation
4. Parecoxib for short-term treatment of acute pain and post-operative pain
5. Zinc oxide + calamine for incontinence-induced dermatitis and diaper dermatitis

Economic Assessment

For Cost-Effectiveness/Utility Analysis (CEA/CUA) + Budget Impact Analysis (BIA) + Household
Financial Impact (HFI) Analysis

1. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with coronary ischemic syndromes (CIS) undergoing coronary angioplasty or atherectomy
2. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) including Non-ST Elevation Myocardial Infarction (NSTEMI) or Unstable Angina (UA)

For Cost-Minimization Analysis (CMA) + BIA + HFI Analysis

3. Paliperidone palmitate 3-months (PP3M) compared to Paliperidone palmitate 1-month (PP1M) among adult patients with schizophrenia who have been adequately treated with PP1M for at least four months

ELSHI Assessment

1. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with coronary ischemic syndromes (CIS) undergoing coronary angioplasty or atherectomy
2. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) including Non-ST Elevation Myocardial Infarction (NSTEMI) or Unstable Angina (UA)
3. Paliperidone palmitate 3-months (PP3M) compared to Paliperidone palmitate 1-month (PP1M) among adult patients with schizophrenia who have been adequately treated with PP1M for at least four months

For interested researchers, kindly take note of the following important dates:

• Deadline of expression of interest: 8 January 2025 (Wednesday)
• Deadline for submission of requirements: 10 working days from the submission of the expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide: